N-3 fatty acids attenuate the risk of diabetes associated with elevated serum nonesterified fatty acids: The multi-ethnic study of atherosclerosis

Diabetes Care

Volumn 38, Issue 4, 2015, Pages 575-580

  Steffen, Brian T ^a   Steffen, Lyn M ^b   Zhou, Xia ^b   Ouyang, Pamela ^c   Weir, Natalie L ^a   Tsai, Michael Y ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; FATTY ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; BIOLOGICAL MARKER; PHOSPHOLIPID;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; COLORIMETRY; DIET RESTRICTION; EDUCATION; FATTY ACID BLOOD LEVEL; FEMALE; GAS CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL; RACE; RISK ASSESSMENT; SEX; SMOKING; AGED; ATHEROSCLEROSIS; BLOOD; COHORT ANALYSIS; DIABETES MELLITUS, TYPE 2; ETHNIC GROUP; ETHNOLOGY; INCIDENCE; MIDDLE AGED; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; BIOMARKERS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DOCOSAHEXAENOIC ACIDS; ETHNIC GROUPS; FASTING; FATTY ACIDS, NONESTERIFIED; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PHOSPHOLIPIDS; RISK FACTORS;

EID: 84962145329     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-1919     Document Type: Article

References (40)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
2. Srikanth S, Deedwania P. Primary and secondary prevention strategy for cardiovascular disease in diabetes mellitus. Cardiol Clin 2011;29:47-70.
3. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE; Diabetes Prevention Program Research Group. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012;379:2243-2251.
4. Pankow JS, Duncan BB, Schmidt MI, et al.; Atherosclerosis Risk in Communities Study. Fasting plasma free fatty acids and risk of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes Care 2004;27:77-82.
5. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 1995;38:1213-1217.
6. Charles MA, Eschwege E, Thibult N, et al. The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study. Diabetologia 1997;40:1101-1106.
7. Salgin B, Ong KK, Thankamony A, Emmett P, Wareham NJ, Dunger DB. Higher fasting plasma free fatty acid levels are associated with lower insulin secretion in children and adults and a higher incidence of type 2 diabetes. J Clin Endocrinol Metab 2012;97:3302-3309.
8. Frohnert BI, Jacobs DR Jr, Steinberger J, Moran A, Steffen LM, Sinaiko AR. Relation between serum free fatty acids and adiposity, insulin resistance, and cardiovascular risk factors from adolescence to adulthood. Diabetes 2013;62:3163-3169.
9. Byrne CD, Maison P, Halsall D, Martensz N, Hales CN, Wareham NJ. Cross-sectional but not longitudinal associations between non-esterified fatty acid levels and glucose intolerance and other features of the metabolic syndrome. Diabet Med 1999;16:1007-1015.
10. Belfort R, Mandarino L, Kashyap S, et al. Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes 2005; 54:1640-1648.
11. Boden G, Cheung P, Stein TP, Kresge K, Mozzoli M. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am J Physiol EndocrinolMetab 2002;283:E12-E19.
12. Boden G, Chen X, Rosner J, Barton M. Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 1995;44:1239-1242.
13. Tripathy D, Mohanty P, Dhindsa S, et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003;52:2882-2887.
14. Liang H, Tantiwong P, Sriwijitkamol A, et al. Effect of a sustained reduction in plasma free fatty acid concentration on insulin signaling and inflammation in skeletal muscle from human subjects. J Physiol 2013;591:2897-2909.
15. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006;116:3015-3025.
16. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996;271:665-668.
17. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005;11:183-190.
18. Song MJ, Kim KH, Yoon JM, Kim JB. Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun 2006;346:739-745.
19. Popp-Snijders C, Schouten JA, Heine RJ, van der Meer J, van der Veen EA. Dietary supplementation of omega-3 polyunsaturated fatty acids improves insulin sensitivity in non-insulin-dependent diabetes. Diabetes Res 1987;4:141-147.
20. Gingras AA, White PJ, Chouinard PY, et al. Longchain omega-3 fatty acids regulate bovine wholebody protein metabolism by promoting muscle insulin signalling to the Akt-mTOR-S6K1 pathway and insulin sensitivity. J Physiol 2007;579:269-284.
21. Gonźalez-Ṕ eriz A, Horrillo R, Ferŕe N, et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: A role for resolvins and protectins. FASEB J 2009; 23:1946-1957.
22. Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010;142:687-698.
23. Rangel-Huerta OD, Aguilera CM, Mesa MD, Gil A. Omega-3 long-chain polyunsaturated fatty acids supplementation on inflammatory biomarkers: A systematic review of randomised clinical trials. Br J Nutr 2012;107(Suppl. 2):S159-S170.
24. Hellmann J, Tang Y, KosuriM, Bhatnagar A, Spite M.ResolvinD1 decreases adipose tissuemacrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J 2011;25:2399-2407.
25. Reinders I, Virtanen JK, Brouwer IA, Tuomainen TP. Association of serum n-3 polyunsaturated fatty acids with C-reactive protein in men. Eur J Clin Nutr 2012;66:736-741.
26. Virtanen JK, Mursu J, Voutilainen S, Uusitupa M, Tuomainen TP. Serum omega-3 polyunsaturated fatty acids and risk of incident type 2 diabetes in men: the Kuopio Ischemic Heart Disease Risk Factor study. Diabetes Care 2014;37:189-196.
27. Kaushik M, Mozaffarian D, Spiegelman D, Manson JE, Willett WC, Hu FB. Long-chain omega-3 fatty acids, fish intake, and the risk of type 2 diabetes mellitus. Am J Clin Nutr 2009;90:613-620.
28. Djouse L, Gaziano JM, Buring JE, Lee IM. Dietary omega-3 fatty acids and fish consumption and risk of type 2 diabetes. Am J Clin Nutr 2011;93:143-150.
29. Brostow DP, Odegaard AO, Koh WP, et al. Omega-3 fatty acids and incident type 2 diabetes: the Singapore Chinese Health Study. Am J Clin Nutr 2011;94:520-526.
30. Zhang M, Picard-Deland E, Marette A. Fish and marine omega-3 polyunsatured fatty acid consumption and incidence of type 2 diabetes: A systematic review and meta-analysis. Int J Endocrinol 2013;2013:501015.
31. Bild DE, Bluemke DA, Burke GL, et al. Multiethnic study of atherosclerosis: objectives and design. Am J Epidemiol 2002;156:871-881.
32. Cao J, Schwichtenberg KA, Hanson NQ, Tsai MY. Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids. Clin Chem 2006;52:2265-2272.
33. Zhang C, Klett EL, Coleman RA. Lipid signals and insulin resistance. Clin Lipidol 2013;8:659-667.
34. Adams JM 2nd, Pratipanawatr T, Berria R, et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 2004;53:25-31.
35. Watt MJ, Barnett AC, Bruce CR, Schenk S, Horowitz JF, Hoy AJ. Regulation of plasma ceramide levels with fatty acid oversupply: evidence that the liver detects and secretes de novo synthesised ceramide. Diabetologia 2012;55:2741-2746.
36. Lee JS, Pinnamaneni SK, Eo SJ, et al. Saturated, but not n-6 polyunsaturated, fatty acids induce insulin resistance: role of intramuscular accumulation of lipid metabolites. J Appl Physiol 2006;100:1467-1474.
37. Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesityrelated diseases. Cell Metab 2013;17:185-196.
38. Lindberg M, Midthjell K, Bjerve KS. Long-term tracking of plasma phospholipid fatty acid concentrations and their correlation with the dietary intake of marine foods in newly diagnosed diabetic patients: results from a follow-up of the HUNT Study, Norway. Br J Nutr 2013;109:1123-1134.
39. Chung H, Nettleton JA, Lemaitre RN, et al. Frequency and type of seafood consumed influence plasma (n-3) fatty acid concentrations. J Nutr 2008; 138:2422-2427.
40. Widjaja A, Morris RJ, Levy JC, Frayn KN, Manley SE, Turner RC.Within- and between-subject variation in commonly measured anthropometric and biochemical variables. Clin Chem 1999;45:561-566.